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Abstract:  Ebolavirus (EBOV) and Marburgvirus (MARV) that compose the filovirus 
family of negative strand RNA viruses infect a broad range of mammalian cells. Recent 
studies indicate that cellular entry of this family of viruses requires a series of cellular 
protein interactions and molecular mechanisms, some of which are unique to filoviruses 
and others are commonly used by all viral glycoproteins. Details of this entry pathway are 
highlighted here. Virus entry into cells is initiated by the interaction of the viral 
glycoprotein1 subunit (GP1) with both adherence factors and one or more receptors on the 
surface of host cells. On epithelial cells, we recently demonstrated that TIM-1 serves as a 
receptor for this family of viruses, but the cell surface receptors in other cell types remain 
unidentified. Upon receptor binding, the virus is internalized into endosomes primarily via 
macropinocytosis, but perhaps by other mechanisms as well. Within the acidified 
endosome, the heavily glycosylated GP1 is cleaved to a smaller form by the low   
pH-dependent cellular proteases Cathepsin L and B, exposing residues in the receptor 
binding site (RBS). Details of the molecular events following cathepsin-dependent 
trimming of GP1 are currently incomplete; however, the processed GP1 specifically 
interacts with endosomal/lysosomal membranes that contain the Niemann Pick C1 (NPC1) 
protein and expression of NPC1 is required for productive infection, suggesting that 
GP/NPC1 interactions may be an important late step in the entry process. Additional events 
such as further GP1 processing and/or reducing events may also be required to generate a  
fusion-ready form of the glycoprotein. Once this has been achieved, sequences in the 
filovirus GP2 subunit mediate viral/cellular membrane fusion via mechanisms similar to 
those previously described for other enveloped viruses. This multi-step entry pathway 
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highlights the complex and highly orchestrated path of internalization and fusion that 
appears unique for filoviruses. 
Keywords:  ebolavirus; marburgvirus; filovirus; virus entry; virus fusion; endocytosis; 
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1. Introduction  
Filoviruses (family Mononegavirales, genera Ebolavirus (EBOV) and Marburgvirus (MARV)) are 
single-stranded, negative-sense RNA viruses that exhibit a unique heterogeneous filamentous 
structure. Both EBOV and MARV infect a wide variety of mammals and this wide tropism has 
complicated the identification of cellular proteins required for viral entry. A hemorrhagic fever is 
caused by these viruses in humans, non-human primates and perhaps other mammals and is associated 
with high morbidity and mortality during outbreaks. No therapeutic drugs or vaccines are currently 
available to treat or prevent filoviral infection. Because of this and the high lethality associated with 
infection, filoviruses are considered Category A Priority Pathogens by NIAID and, in recent years, 
much research has focused on understanding how these viruses bind to and enter permissive cells. 
2. Synthesis of Filoviral GPs 
The EBOV genome encodes seven genes, including the glycoprotein (GP) gene. The GP gene 
encodes for two known soluble GP forms (sGP and ssGP) [1,2]. The precise functions of the soluble 
forms of EBOV GP are unknown, but it is speculated that they are involved in immune evasion, as 
most of the antibodies during a natural Zaire EBOV (ZEBOV) infection are against sGP [3].   
Full-length EBOV GP is not directly encoded by the GP gene, but is produced by a transcriptional 
editing event that shifts the reading frame of about 20% of the GP transcripts. In contrast, while 
MARV also encodes seven genes, its GP is directly encoded by the GP gene and soluble forms of 
MARV GP are not thought to be synthesized from viral transcripts.  
 Precursor GP is cleaved by the host enzyme furin in the Golgi apparatus, resulting in the formation 
of two GP subunits, GP1 and GP2. GP1 contains the receptor binding domain (RBD) and is responsible 
for interacting with one or more cellular receptors. This interaction is believed to mediate virus entry 
into the endosomal compartment. GP2 contains a fusion loop, heptad repeat regions, the transmembrane 
domain and a short cytoplasmic tail. While furin processing of the filovirus GP routinely occurs within 
the Golgi apparatus before the glycoprotein is expressed on the plasma membrane, proteolytic clipping 
is not required for virion infectivity [4]. The cleaved subunits are linked by a disulfide bond to 
generate a GP1,2 heterodimer that is located on the surface of virions and is approximately 150 kDa 
in size [5].  Viruses 2012, 4  
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3. Structure of Filovirus GPs 
As a class I viral fusion protein, GP1,2 exists as a trimer of GP1 and GP2 heterodimeric subunits and 
is found in its full-length, heavily glycosylated, pre-fusion form on the surface of newly budded 
virions. This pre-fusion class I glycoprotein conformation is thought to be a metastable state, that upon 
the appropriate set of triggers, will convert to its post-fusion, low-energy form [6]. The conformational 
change from a pre-fusion to post-fusion structure provides the energy to permit the viral and cellular 
membranes to fuse and thereby release the viral core into the cytoplasm. The events that are required 
for filovirus/cellular membrane fusion to occur have yet to be completely elucidated, but current 
studies are unraveling these steps and are highlighted here.  
Several EBOV GP crystal structures have been instrumental in understanding the conformational 
alterations that are required as the glycoprotein changes from the metastable, pre-fusion state to the 
low-energy, post-fusion form. Lee et al. elucidated the trimeric structure of pre-fusion, mucin   
domain-deleted EBOV GP1,2 ectodomain [7], whereas, two groups independently solved the trimeric 
GP2 six helix bundle structure that is formed during fusion events [8,9]. 
4. GP1 
Mature GP1 is composed of three distinct domains: the RBD, the glycan cap and a heavily O-linked 
glycosylated mucin-like domain. The RBD in mature ZEBOV GP1 is located from amino acid ~54 to 
201 and composed of a base region and a region that interacts with one or more receptors on the 
surface of cells (Figure 1) [10]. While RBDs of the different EBOV strains are relatively conserved, 
only 47% identity between EBOV and MARV RBDs exists. Nonetheless, EBOV and MARV GP 
pseudovirions compete with each other for filoviral GP1,2-dependent entry into permissive cells, 
indicating that a common receptor or receptors are used by both viruses [10,11]. 
Amino acids 33 through 69 and three additional short downstream regions interact with GP2, 
serving as the base of the RBD. Several linearly discontinuous regions from amino acids 70 to 190 sit 
above the base forming a series of beta sheets. Residues both in beta sheets and adjacent loops have 
been implicated in cell binding, leading to the conclusion that the receptor binding site (RBS) is 
located in this region of the RBD [12,13]. GP1 residues 227 to 313 encode for a “glycan cap” that is 
extensively N-linked glycosylated and sits distal to the RBD from the surface of the virion. The glycan 
cap may protect the RBS from antibodies [3]. This glycan cap also interacts with two regions of GP2, 
including the internal fusion loop of GP2 that is critical for GP2-mediated membrane fusion [7]. The 
glycan cap/GP2 interaction restricts the availability of the fusion peptide, preventing pre-mature fusion 
events. Finally, filovirus GP1 contains a mucin-like domain at the carboxy terminus from amino acids 
310 to 511. This region is heavily glycosylated with both N- and O- linked glycans [7]. While the 
EBOV mucin domain is not required for virus entry [14,15], several roles for this domain have been 
suggested. Like the glycan cap, it may shield GP RBS residues from immune recognition on free 
virus [7]. In addition, the mucin domain causes cell rounding, masking of a number of cell surface 
markers and cytotoxicity that is not observed upon expression of mucin domain-deleted EBOV GP 
[15,16]. The shielding effect of the bulky mucin domain of the RBD of GP1 is thought to also obstruct Viruses 2012, 4  
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RBS interactions with adherence factors and receptors since removal of this domain enhances EBOV 
titers. Similar attempts to delete the MARV mucin domain have proved unsuccessful [11].  
Figure 1. Structure of the pre-fusion EBOV GP. (A,B) Structure of the trimer. Side view 
of the EBOV GP trimer is shown in A. Top-down view of the EBOV GP trimer is in B. 
Two of the three trimers are shown as space filling structures with GP1 in lighter grey and 
GP2 as dark grey/black. The third GP1,2 heterodimer of the trimer is depicted as a ribbon 
structure with GP1 shown in teal and the GP2 subunit shown in tan. (C,D) Ribbon diagrams 
of a single heterodimer of GP1,2. Domains in GP1 are highlighted in C, whereas domains in 
GP2 are highlighted in D. In panel C, the base domain of GP1 that interacts with GP2 is 
shown in royal blue, the head domain is shown in teal with the beta-strands and adjacent 
loop region containing the RBS highlighted in red and the glycan cap is shown in gold. 
GP2 is shown in grey. In panel D, the internal fusion loop (IFL) that is flanked by   
beta-strands is shown in dark brown and heptad repeat region 1 is shown in tan. The 
interaction of the IFL with GP1 residues from an adjacent subunit is evident in panel A. All 
EBOV GP graphics (PDB accession number 3CSY) were produced with PyMol. 
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5. GP2 
Filovirus GP2 is similar to other class I viral glycoproteins that mediate fusion events. GP2 is 
composed of a fusion loop found near the amino terminus followed by a N-terminal heptad repeat 
region, a C-terminal heptad repeat region, a transmembrane region and a short cytoplasmic tail [6,8,9]. 
In the pre-fusion form on the surface of newly budded virions, the fusion loop and N-terminal heptad 
region are integral regions of the GP1/GP2 trimeric structure, forming a platform or base upon which 
GP1 sits (Figure 1). In contrast, the C-terminal heptad repeat region in the pre-fusion form may contain 
little structure and was deleted in the crystallization studies and it is not thought to contribute to the 
metastable, pre-fusion form of GP [7]. Not surprisingly, both the fusion loop and N-terminal heptad 
repeat are conserved (>70% identity) between ZEBOV and the Musoke strain of MARV, but the 
remaining portions of GP2 have limited identity. Site directed mutagenesis studies of EBOV or MARV Viruses 2012, 4  
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GP2 [14,17–23] suggest a similar chain of events to those previously reported for other class I 
viral glycoproteins leads to viral/cell membrane fusion [6,24,25]. These events will be discussed in 
detail below.  
6. The Role of Cell Surface Proteins in Filovirus GP-Dependent Entry 
While progress is being made to identify cell surface proteins that enhance filovirus 
transduction/infection, the advancement of this area of research has been slow. In part this is due to the 
broad tropism of filoviruses for a variety of different cell types as well as the ability of these viruses to 
infect cells from a wide range of species [26–37]. One classical approach to identifying virus receptors 
that has been used is the introduction of a cDNA library from a permissive cell into a cell that is not 
permissive for the virus [38–40]. However, for reasons that are not entirely clear, this type of study has 
not been successful in identifying cell surface proteins that directly interact with EBOV GP to mediate 
virus entry [41,42]. Instead, another screening approach that correlated gene expression in a large 
panel of human cells with EBOV GP-dependent transduction proved more productive and allowed us 
to identify a surface receptor for these viruses [43]. The cell surface protein we identified, TIM-1, as 
well as other cell surface proteins that enhance filovirus infectivity are discussed in detail below.  
6.1. C-Type Lectins 
C-type lectin family members L-SIGN, DC-SIGN and hMGL have been shown to enhance filovirus 
entry [19,44–48]. Studies have demonstrated that both the mucin domain and the glycan cap of GP1 
interact with C-type lectins [47,49]. However, as both of these regions can be deleted from EBOV GP1 
without loss of viral transduction efficiency [16,50–52], it is likely that C-type lectins increase 
filovirus attachment to cells rather than serving as cellular receptors that mediate internalization of the 
virus into endosomes [53]. A similar adherence function for C-type lectins has been identified for other 
enveloped viruses such as HIV [54]. 
6.2. β1 Integrins 
Early studies found that surface expression of some integrins was down regulated upon transfection 
of full-length EBOV GP [15,55,56]. In addition, EBOV GP-mediated pseudovirion entry is reduced by 
either antibodies targeting β1 integrins or a soluble form of β1 integrins [56]. These characteristics 
suggested that one or more integrin subunits might serve as receptors for filoviruses. However, no 
direct interaction between any portion of EBOV GP and a member of the β1 integrin family has been 
identified. More recent studies implicate β1 integrin in stimulation of endosomal protease events that 
are required for productive EBOV transduction, thus reducing the likelihood of β1 integrins serving as 
bona fide filoviral receptors [57].  
6.3. Tyro3 (TAM) Family Tyrosine Kinase Receptors 
The TAM family member Axl was first implicated in filovirus entry through a cDNA screen that 
introduced Vero E6 cell cDNA into poorly permissive Jurkat T cells [41]. Axl is a tyrosine kinase 
receptor that is found on the plasma membrane in a variety of different cell types and enhances cell Viruses 2012, 4  
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migration, division and viability upon activation [58]. Shimojima et al. demonstrated that anti-Axl 
antibodies blocked EBOV transduction of some cells, whereas these antibodies had no effect on 
transduction of other cells [41]. Mapping studies indicated that amino acid residues in both the 
ectodomain and the cytoplasmic tail of Axl were required for filovirus entry enhancement [59]. 
Subsequently, a screen performed in our laboratory also identified Axl as being important in EBOV 
GP-dependent entry [60]. Through the use of multiple biochemical inhibitors, siRNA and anti-Axl 
antibodies, we defined a role for Axl in EBOV uptake [61], demonstrating that Axl expression enhances 
macropinocytosis in some cells. As macropinocytosis is a principal uptake mechanism of filoviruses 
[62,63], increased Axl surface expression leads to greater virus internalization. However, Axl does not 
appear to interact directly with EBOV GP to promote viral internalization and therefore is unlikely to 
serve as a filoviral receptor [60].  
6.4. TIM-1 
Our lab performed a comparative genomic analysis (CGA) screen [64] to identify cellular genes 
whose expression highly correlated with EBOV pseudovirion transduction [43]. This screen showed a 
positive correlation between EBOV transduction and expression of a series of cellular proteins that 
were previously appreciated to enhance EBOV transduction (C-type lectins, integrins and Axl). 
Interestingly, expression of the T-cell immunoglobulin mucin domain-1 (TIM-1) gene proved to be 
one of the strongest positive correlations. Subsequent studies demonstrated that expression of TIM-1 in 
poorly permissive cells enhanced EBOV entry and loss of surface-expressed TIM-1 in highly 
permissive cells abrogated filovirus infection/transduction. Furthermore, TIM-1 and the mucin 
domain-deleted EBOV GP interacted, and removal of the glycan cap enhanced the specificity of GP 
interaction with TIM-1-expressing cells [43]. In total, these findings have led us to propose TIM-1 as a 
cell surface receptor for filoviruses. As epithelial cells are the only relevant cell type that expresses 
TIM-1, it is likely that other as of yet unidentified surface receptors will also prove to be important in 
mediating filovirus entry.  
7. Mechanism(s) of Filoviral GP-Mediated Entry into Permissive Cells 
The cellular uptake pathways mediating filovirus entry remain controversial despite numerous 
studies. The three most common and well studied endocytic pathways—caveolin-dependent endocytosis, 
clathrin-dependent endocytosis and macropinocytosis—have all been implicated in filovirus entry. 
Early studies reported that the caveolae vesicular system and/or lipid raft domains were important for 
EBOV GP-mediated entry [65–67]. However, it was demonstrated that overexpression of Caveolin 1 
in the poorly permissive lymphocytic cell line CEM did not enhance levels of EBOV GP-dependent 
transduction, suggesting that caveolae may not play a role in filovirus entry [36]. Since that time 
several groups have also implicated clathrin-dependent entry mechanisms in filovirus entry [68–71].  
In parallel, other groups using virus-like particles (VLPs) and/or infectious filovirions identified 
macropinocytosis as a main and perhaps sole mechanism of filovirus uptake [62,63]. Several groups 
have found that EBOV GP-dependent entry can occur through a variety of different uptake mechanisms 
including caveolae, clathrin-coated pits and through actin- and microtubule-dependent pathways such 
as macropinocytosis [61,70,71] within the same cell population.  Viruses 2012, 4  
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A number of these uptake studies that identified caveolin and/or clathrin as important in entry used 
EBOV GP pseudotyped lentiviruses or vesicular stomatitis virus (VSV) as the cargo and an argument 
has been made that these smaller viral particles do not accurately represent the size constraints that 
may limit the uptake options of a filovirion that can be greater than 10 µM in length [72]. While a role 
for caveolin- and clathrin-dependent pathways in infectious filoviral entry remains to be demonstrated, 
it should be noted that several large, intracellular bacteria or parasites have been found to use either 
caveolin- or clathrin-dependent pathways, suggesting that the size of these vesicles can be expanded to 
meet the size of the cargo [73–75]. In addition, it is likely that the mechanism of EBOV uptake may be 
cell-dependent as both Green African Monkey cells (Vero) [62,63] and human neuroblastoma cells 
(SNB-19) [61] both primarily use macropinocytosis for EBOV uptake. However, the signaling 
pathways that are required for virus entry is cell-specific since Vero cells require activation of the 
PI3K/Akt pathway, whereas SNB-19 cells require PLC activation [61].  
8. Proteolytic Processing of EBOV GP1,2 into a Fusion-Active Form 
Unlike some other class I viral glycoproteins, no evidence exists that EBOV GP1 undergoes 
conformational changes upon binding to a cell surface receptor. Presumably receptor/virus interactions 
lead directly to virus internalization into endosomes; however, this has not been demonstrated directly 
to date. Characterization of the endosomal vesicles mediating EBOV uptake is limited. Saaed et al. 
have demonstrated that the Early Endosome Antigen 1 (EEA1) colocalizes with EBOV virus particles 
in endosomes early during infection of Vero cells [62], whereas Nanbo et al. have shown association 
of EBOV particles lacking VP30 associated with the sorting nexin 5 (SNX5) within 10 minutes of 
transduction [63]. Early and late endosomal proteins, Rab5 and Rab 7, respectively, have also been 
shown to be required for productive infection [62,63]. Several GTPases previously implicated in 
endocytosis, RhoB, Rac1 and CDC42, are also important for EBOV GP-dependent transduction, 
providing additional insights into trafficking pathways used by these viruses [63,76].  
As the vesicles traffic into the cell, they become acidified. For some viral fusion proteins, the 
combination of receptor engagement and endosomal acidity is sufficient for conformational changes 
that lead to viral/cellular membrane fusion [77–79]. However, that is not the case for filoviruses. 
Instead, multiple low pH-dependent endosomal and lysosomal proteolytic proteins are involved in 
EBOV GP1 processing, priming a multi-step process that ultimately results in a small EBOV GP1,2 
trimer that serves as the fusion-ready form of the glycoprotein. It is believed that this processed, 
fusion-ready form is then triggered by additional events to a conformationally stable state, resulting 
in fusion. 
As endosomal vesicles mature into late endosomes and the vesicular pH drops, activation of 
endosomal cysteine proteases Cathepsin L and B occurs. These cathepsins sequentially process EBOV 
GP1 into smaller forms [50,51]. Cathepsin L proteolysis first removes a substantial portion of EBOV 
GP1, generating an approximate 50 kDa GP1,2 species that lacks both the glycan cap and mucin domain 
of GP1 [50,51]. Subsequently, GP1 is further trimmed by both Cathepsin L and B to generate a much 
smaller form of GP1. The exact size of this smaller GP1 remains controversial, but is between 17 
and 19 kDa [50,51]. Irrespective of the exact size of the processed form, prevention of endosomal 
acidification or inhibition of Cathepsin B activity abolishes EBOV infectivity [50–52,70]. Viruses 2012, 4  
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Interestingly, this processing may be insufficient for productive EBOV infection as studies have 
demonstrated that the smaller 17–19 kDa Cathepsin L and B-cleaved form cannot infect cells entirely 
lacking cathepsins [80]. Thus, it has been proposed that additional cathepsin-dependent GP1 processing 
is required to generate the fusion-ready form of the glycoprotein [80]. The size and composition of this 
smaller form is not known. In contrast to these studies, a recent study demonstrated that a thermolysin-
trimmed GP1 that is believed to generate a GP1 that is similar to the Cathepsin L and B-cleaved form 
can be triggered to bind to liposomes at elevated temperatures under low pH and mildly reducing 
conditions [81]. This new study suggests that at least under these conditions this GP conformation is a 
fusion-ready form. 
Given the apparent importance of cathepsin cleavage for the generation of a fusion-ready form of 
the filovirus glycoprotein, it is surprising that studies have demonstrated that Cathepsin L and B 
cleavage events can be sidestepped by the virus [80,82]. Martinez et al. have shown that in   
monocyte-derived dendritic cells, Cathepsin B is required for EBOV infection, but not Cathepsin L [82]. 
These observations were confirmed in Vero cells in a recent study by Wong et al. [80]. This group also 
extended the finding by selecting an infectious, recombinant VSV encoding EBOV GP over several 
passages to become resistant to the Cathepsin B inhibitor CA074 [80]. Six different mutants were 
identified that conferred Cathepsin B independence. Many of these mutations sit at the interface of GP1 
and GP2 and the selected mutations were thought to alter the GP structure such that enhanced 
proteolysis by one or more currently undefined cysteine proteases was possible. Thus, while Cathepsin 
B and L independence can be achieved by filoviruses, processing by one or more additional cysteine 
proteases is still required for production of the fusion-ready form.  
9. NPC1 
Most recently, two groups independently identified a novel host protein essential for EBOV 
infection. Cote et al. screened a library of small chemical molecules to find those that inhibited EBOV 
GP pseudovirion entry into Vero cells [83], whereas Carette et al. utilized a genome-wide screen in 
mutagenized haploid human cells to look for those cells resistant to EBOV GP-dependent entry [84]. 
Each group was able to deduce that disruption of one endosomal/lysosomal membrane protein, 
Niemann-Pick C1 (NPC1), could significantly reduce EBOV entry into a variety of cell populations. 
NPC1 is primarily a membrane bound, late endosomal/lysosomal protein that is critical for cholesterol 
absorption and homeostasis. Those individuals lacking a functional NPC1 exhibit an abnormally high 
accumulation of cholesterol in the lysosomes of their cells, leading to altered protein and lipid 
trafficking with most cases resulting in fatality by 18 months of age [85]. Cells where NPC1 function 
has been biochemically disrupted or cells lacking NPC1 showed a resistance to EBOV infection [83,84]. 
Clearance of cholesterol from NPC1 null cells by cultivation in lipoprotein-depleted media did not 
rescue EBOV infection, indicating that the NPC1 protein itself, and not aberrant cholesterol transport, 
was important for EBOV entry [84]. Cote et al. also showed that the expression of NPC1 and not its 
cholesterol transport activity were critical for EBOV entry [83].  
As the NPC1 protein is primarily located on the endosomal and lysosomal membranes, NPC1 has 
been proposed to serve as an entry factor downstream of EBOV GP engagement of attachment 
factors/receptor(s) at the cell surface. Consistent with a vesicular role for NPC1, Cote et al. showed Viruses 2012, 4  
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that a soluble form of thermolysin-cleaved EBOV GP, but not uncleaved GP containing the glycan 
cap, bound to lysosomal membranes of NPC1-transfected CHO cells [83]. Thus, at least in this over 
expression system, proteolytically-processed EBOV GP appeared to interact with NPC1-containing 
membranes, suggesting that these interactions may be important for filovirus entry events that occur in 
late endosomes and/or in lysosomes. EBOV GP-mediated attachment and entry into early endosomes 
was unaffected in NPC1-defective cells; however, electron micrographs of NPC1 null cells infected 
with EBOV GP pseudotyped virus show the accumulation of perinuclear vesicles laden with EBOV 
GP pseudovirions that were positive for the lysosomal marker LAMP1 [84]. Therefore, Carette et al. 
have proposed that NCP1 is crucial for viral membrane fusion and escape from the lysosomal 
vesicle [84]. At present, the precise role of NPC1 during the EBOV entry process remains to be fully 
elucidated. In addition, investigations into the precise location of filovirus fusion events within 
endosomal compartments will provide important insights into these events. 
Interestingly, an inhibitor of NPC1, U18666A, has recently been shown to block entry of   
several pathogens, including the flavivirus Dengue [86]. This inhibitor also inhibited entry of hepatitis 
C virus [87] as well as prions [88], suggesting that this cholesterol transporter may be critical for 
passage of a number of viruses, and perhaps other pathogens, through endosomes. Most recently, a 
more definitive role for NPC1 in hepatitis C virus entry has been determined through the use of 
additional biochemical agents [89]. Future studies exploring lipid accumulation and changes in lipid 
composition within the endosomal pathway could significantly enhance the understanding of the novel 
role of NPC1 specifically in filoviral entry and more generally in endosomal trafficking of a number of 
enveloped viruses.  
10. Characterized Filovirus Fusion Events 
As described above, the GP1 portion of EBOV GP1,2 allows delivery of the filovirion to an 
endosome where conditions become progressively more favorable for generating the fusion-ready form 
of GP1,2. Trimming of GP1,2 by host cathepsins (or artificially by thermolysin) enhances interaction of 
GP with TIM-1 [43] and permits NPC1 binding [83]. Whether EBOV GP interaction, with either of 
these molecules, directly mediates GP2 fusion events remains to be determined. 
Filovirus GP2 contains an N-terminal internal fusion loop of 45 residues defined by a disulfide 
linkage between cysteines 511 and 556 [3,7]. A core hydrophobic sequence of 16 amino acids within 
this loop is thought to insert into host endosomal membranes, initiating membrane fusion events. 
Within the intact GP heterodimer, the hydrophobic, internal fusion loop is flanked by antiparallel   
β-strands composed of the most N-terminal portion of the internal fusion loop and the N-terminal 
region of first heptad repeat region. The fusion loop is restrained by GP1 residues from a neighboring 
subunit, preventing premature fusion events [3,7,90]. Cathepsin-dependent processing alone is 
insufficient to trigger insertion of the fusion loop into liposomes [81,91].  
When the EBOV internal fusion loop interacts with liposomal membrane mimetics, lipid mixing is 
promoted with a parallel structural change in the loop [90]. In a neutral pH, lipid environment, the 
antiparallel β-strands that flank the fusion loop lose their structure, generating a more alpha helical 
content with a flattened extended loop structure. Under low pH conditions (<pH 5.5) in the presence of 
lipids, this flattened loop structure broadens out, forming a more hook-like structure [90]. It has been Viruses 2012, 4  
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previously shown that specific proline residues contained within the central portion of the fusion loop 
facilitate this lipid membrane interaction [21,23,92,93]. The insertion of GP2 into host membranes 
causes an extension of the GP2 trimers into an energetically unfavorable state. This also causes the two 
heptad repeat regions (HRs) within GP2 to be fully exposed to the physiological conditions within the 
acidified host endosome, which may aid in further triggering of GP2 to promote final collapse of the 
two HRs [81].  
The N-terminal GP2 heptad repeat region (HR1) is a highly ordered, alpha-helical structure that 
serves as a platform or base for GP1 and contains residues that are necessary for interactions with other 
GP2 HR1s to form the trimeric structure of the pre-fusion GP [3,7]. In the pre-fusion form, HR1 does 
not interact with the carboxy terminal heptad repeat region (HR2). Within the intact, pre-fusion trimer, 
HR2 appears to be disordered and was not included in the crystallized structure [7].  
Following insertion of EBOV GP2 fusion loop into the host membrane, the EBOV GP2 trimeric 
heptad repeats collapse and form a six-helix bundle containing three HR1 and HR2 domains. The 
collapse into a coiled coil structure draws the two membranes into proximity allowing partial fusion 
(hemifusion) of the viral membrane and the host endosomal membrane [8,9]. Hemifusion eventually 
leads to complete fusion of the viral and host endosomal membranes, and an opening through which 
the viral RNA and its associated proteins can be released into the host cell cytoplasm, where the viral 
life cycle continues. 
11. Potential Therapeutics against Filovirus Entry 
This complex set of entry events summarized in Figure 2 provides numerous potential avenues for 
the development of antiviral therapies against filovirus infection. These possibilities include: 
(1) interfering with adherence to permissive cells by blocking C-type lectin (or other adherence factor) 
interactions with the filoviral GP; (2) blocking binding of GP to TIM-1 and/or other cellular receptors 
that are identified in the future; (3) preventing virus uptake by blocking macropinocytosis;   
(4) interfering with cathepsin activity; (5) inhibiting availability of NPC1 within the lysosomal 
compartment and (6) blocking HR1/HR2 (coiled coil) interactions. It is likely that some of these steps 
will be more amendable than others to the development of antivirals that have minimal or no 
cytotoxicity. Regardless, elucidation of these entry events provides clear targets for the development of 
drugs that may prevent both filovirus infection and disease.  Viruses 2012, 4  
 
 
268
Figure 2. Model for filoviral entry. Trimers of filoviral GPs on virions interact with both 
attachment factors (C-type lectins) and receptors (TIM-1) on the surface of permissive 
cells. Attachment factors are likely to concentrate virions on cells before receptor 
engagement and virion internalization by macropinocytosis. Macropinocytosis is enhanced 
by tyrosine kinase receptors such as TAM family members. Following endosomal 
acidification, Cathepsins L and B trim the EBOV GP to a smaller form that needs at least 
one as yet undetermined factor to elicit GP fusion with host endosomal membranes. This 
smaller form of GP is able to interact with both TIM-1 and the endosomal portion of the 
NPC1 protein; however, whether GP and TIM-1 interact within endosomes is not known. 
The energetically unfavorable insertion of the EBOV GP2 fusion loop into host endosomal 
membranes (i) is followed by the energetically favorable collapse of EBOV GP into a  
six-helix bundle (ii) allowing for lipid mixing and hemifusion of host and viral membrane 
lipids (ii). Finally, the hemifused host and viral membranes resolve and a complete pore is 
formed (iii) through which the viral genomic complex passes into the cytoplasm, allowing 
the viral replication cycle to continue.  
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